INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), een farmaceutische gigant met een marktkapitalisatie van $ 735 mld. en een ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

Weight loss drugs are exploding in popularity across the country with many calling them game-changers when it comes to treating obesity and all the medical cond ...

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising ...

By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

The U.K. is asking patients whose pancreas became dangerously inflamed after taking obesity drugs like Wegovy and Zepbound to ...

Novo Nordisk blijft marktaandeel en jaar-op-jaar groei verliezen, waarbij het laagste aandeel en groeipercentage in meer dan een jaar werd bereikt, merkte het bureau op. Deze daling houdt aan ondanks ...